Changes of biological features in breast cancer cells determined by primary chemotherapy

Breast Cancer Research and Treatment

Volumn 44, Issue 3, 1997, Pages 185-192

  Frassoldati, Antonio ^a,b   Adami, Francesca ^a   Banzi, Chiara ^a   Criscuolo, Mario ^a   Piccinini, Lino ^a   Silingardi, Vittorio ^a  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^b UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

Biological features; Breast cancer; Primary chemotherapy

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; CYCLINE; CYCLOPHOSPHAMIDE; EPIDERMAL GROWTH FACTOR RECEPTOR; ESTROGEN RECEPTOR; FLUOROURACIL; HORMONE RECEPTOR; KI 67 ANTIGEN; METHOTREXATE; PROTEIN BCL 2; PROTEIN P53;

ADULT; AGED; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CLINICAL ARTICLE; CYTOLOGY; FEMALE; HISTOLOGY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; PHENOTYPE; PRIORITY JOURNAL;

ADULT; AGED; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BREAST NEOPLASMS; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEMALE; FLUOROURACIL; HUMANS; IMMUNOHISTOCHEMISTRY; METHOTREXATE; MIDDLE AGED; PROLIFERATING CELL NUCLEAR ANTIGEN; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 0030740799     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1005875002458     Document Type: Article

References (32)

1. Scholl SM, Fourquet A, Asselain B et al.: Neoadjuvant versus adjuvant chemotherapy in premenopausal patients with tumors considered too large for breast conserving surgery: preliminary results of randomized trial: S6. Eur J Cancer 30A: 645-652, 1994
2. Fisher B, Rockette H, Robidoux A et al.: Effect of preoperative therapy for breast cancer on local regional disease: first report of NSABP B18. Proc Am Soc Clin Oncol 13: 64 (Abs 57), 1994
3. Fisher B, Wickerham DL: Preoperative systemic therapy for the treatment of primary breast cancer. In: Powles TJ, Smith IE (eds) Medical Management of Breast Cancer. London, UK, Martin Dunitz, 1991, pp 281-285
4. Bonadonna G, Veronesi U, Brambilla C et al.: Primary chemotherapy to avoid mastectomy in tumors with diameters of three centimeters or more. J Natl Cancer Inst 82: 1539-1545, 1990
5. McGuire WL, Clark GM: Prognostic factors and treatment decision in axillary node negative breast cancer patients. N Engl J Med 326: 1756-1761, 1992
6. Chevallier B, Heintzmann F, Mosseri V et al.: Prognostic value of estrogen and progesterone receptors in operable breast cancer. Cancer 62: 2517-2524, 1988
7. 3H-thymidine-labeling index as a prognostic indicator in node-positive breast cancer. J Clin Oncol 8: 1321-1326, 1990
8. Remvikos Y, Mosseri V, Zajdela A et al.: Prognostic value of S-phase fraction of breast cancer treated by primary radiotherapy or neo-adjuvant chemotherapy. Ann NY Acad Sci 698: 193-203, 1993
9. Wintzer HO, Zipfel I, Shulte J et al.: Ki67 immunostaining in human breast tumors and its relationship to prognosis. Cancer 67: 421-428, 1991
10. Gillett CE, Barnes DM, Camplejohn RS: Comparison of three cell cycle associated antigens as markers of proliferative activity and prognosis in breast carcinoma. J Clin Pathol 46: 1126-1128, 1993
11. Isola J, Visakorpi T, Holli K et al.: Association of overexpression of tumor suppressor protein p53 and rapid cell proliferation and poor prognosis in node-negative breast cancer patients. J Natl Cancer Inst 84: 1109-1114, 1992
12. Tandon AK, Clark GM, Chamness GC et al.: HER-2/neu oncogene protein and prognosis in breast cancer. J Clin Oncol 7: 1120-1128, 1989
13. Sainsbury JRC, Malcolm AJ, Appleton DR et al.: Presence of epidermal growth factor receptor as an indicator of poor prognosis in patients with breast cancer. J Clin Pathol 38: 1225-1228, 1985
14. Silvestrini R, Veneroni S, Daidone MG et al.: The bcl-2 protein: A prognostic indicator strongly related to p.53 protein in lymph node negative breast cancer patients. J Natl Cancer Inst 86: 499-504, 1994
15. Charpin C, Vielh P, Duffaud F et al.: Quantitative immunocytochemical assays of p-glycoprotein in breast carcinomas: Correlation to messenger RNA expression and to immunohistochemical prognostic indicators. J Natl Cancer Inst 86: 1539-1545, 1994
16. Contesso G, Saccani Jotti G, Bonadonna G: Tumor grade as prognostic factor in primary breast cancer. Eur J Cancer Clin Oncol 25: 403-409, 1989
17. Lipponen P, Aaltomaa S, Kosma VM et al.: Apoptosis in breast cancer as related to histopathological characteristics and prognosis. Eur J Cancer 30A: 2068-2073, 1994
18. Fisher B: Preoperative chemotherapy: A model for studying the biology and the therapy of primary breast cancer. J Clin Oncol 13: 537-540, 1995
19. Klijn JG, Berns EM, Foekens JA: Prognostic factors and response to therapy in breast cancer. Cancer Surv 18: 165-198, 1993
20. Wosikowski K, Saceda M, Martin MB et al.: Phenotypic changes associated with the development of multidrug resistance in human breast cancer cells. Proc Am Assoc Cancer Res 34: A133 (Abst), 1993
21. Nic NH, Hadlay-Hull C, Jenkins JG et al.: SPSS (Statistical Package for the Social Sciences). McGraw Hill, New York, 1979
22. Waller U: Giant nuclei after myleran therapy and splenic irradiation. Pathol Microbiol 23: 283-290, 1960
23. Kennedy S, Merino SJ, Swain S et al.: The effects of hormonal and chemotherapy on tumoral and non neoplastic breast tissue. Hum Pathol 21: 192-198, 1990
24. Skipper HE: Kinetics of mammary tumor cell growth and implications for therapy. Cancer 28: 1479-1499, 1971
25. Rainsbridge SA, Gillett CE, Seymour AM et al.: The effects of chemotherapy on morphology, cellular proliferation, apoptosis and oncoprotein expression in primary breast carcinoma. Brit J Cancer 70: 335-341, 1994
26. Clark GM: Prognostic and predictive factors. In: Harris JR, Lippman ME, Morrow M et al. (eds): Disease of the breast. Lipincott-Raven, Philadelphia, 1996, pp. 461-485
27. Baserga R: Growth regulation of the PCNA gene. J Cell Sci 98: 433-436, 1991
28. Chan WK, Poulsom R, Long QL et al.: Bcl-2 expression in invasive mammary carcinoma: Correlation with apoptosis, hormone receptors and p53 expression. J Pathol (Suppl) 169: 153A, 1993
29. Allred CD, Clark GM, Elledge R et al.: Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J Natl Cancer Inst 85: 200-206, 1993
30. Sainshury J, Farndon J, Sherbet G et al.: Epidermal-growth-factor receptors and estrogen receptors in human breast cancer. Lancet i: 364-366, 1985
31. Murayama Y, Kurata S, Mishima Y: Regulation of human estrogen receptor gene, epidermal growth factor receptor gene, and oncogenes by estrogen and antiestrogen in MCF.7 cell. Cancer Detect Prev 13: 103-107, 1988
32. Baselga J, Mendelsohn J: The epidermal growth factor receptor as a target for therapy in breast carcinoma. Breast Cancer Res Treat 29: 127-138, 1994